Skip to main content
Premium Trial:

Request an Annual Quote

Expression Pathology Changes Name to OncoPlex Diagnostics, Plans 2012 Launch of Lung Cancer Test


Clinical proteomics firm Expression Pathology has changed its name to OncoPlex Diagnostics and opened a CLIA laboratory in Rockville, Md.

The company announced last week that by the end of the year it plans to launch a test, run out of its new CLIA facility, for distinguishing adenocarcinoma from squamous cell carcinoma in lung cancer patients.

The test will use formalin-fixed paraffin embedded tissue, making it, according to OncoPlex, the first clinical proteomics test for cancer to do so. The company also said that it plans to introduce additional tests in 2013, including a multiplex breast cancer assay.

OncoPlex uses selected-reaction monitoring mass spec combined with proprietary technology for solubilizing peptides and proteins in FFPE tissue, enabling detection and quantitation of proteins from this widely used sample source.